GlassScriptPhysician profile
Benjamin W Verdine
NPI 1710921986
$672.58
in general payments reported to CMS, 2019-2025
14 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.29 · 2020: $73.05 · 2021: $152 · 2022: $65.68 · 2023: $107 · 2024: $75.21 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $332.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $131.72 | 2019-2023 | Xiaflex |
| Endo USA, INC. | $110.51 | 2024-2025 | Xiaflex |
| Tela Bio, INC. | $92.11 | 2021-2022 | |
| Elite Orthopedics, LLC | $85.64 | 2019-2025 | |
| Abbvie INC. | $68.57 | 2023-2024 | |
| Davol INC. | $37.43 | 2022 | |
| Acumed LLC | $30.56 | 2025 | Acumed |
| Sientra, INC. | $26.15 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $18.13 | 2020 | |
| Axogen | $17.18 | 2019 | |
| Allergan, INC. | $15.62 | 2022 | |
| Solventum Corporation | $13.97 | 2025 | Activ.A.C., V.A.C.Ulta |
| Misonix INC | $13.34 | 2020 | |
| Bioventus LLC | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Verdine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.